Literature DB >> 26617692

Poly (ADP-ribose) synthetase inhibitor has a heart protective effect in a rat model of experimental sepsis.

Lianshuang Zhang1, Jinpeng Yao2, Xifeng Wang3, Hongxing Li1, Tongshen Liu1, Wei Zhao1.   

Abstract

UNLABELLED: The aim of this study is to investigate whether PARP inhibitor could reduce cell apoptosis and injury in the heart during sepsis.
MATERIALS AND METHODS: 60 healthy male Sprague-Dawley (SD) rats were randomly divided into 4 groups---sham group, modal group, 3-AB pretreatment group and 3-AB treatment group, 15 rats per group. The cecal ligation and puncture (CLP) model of sepsis was used. The following were determined--levels of malondialdehyde (MDA), ATP and nicotinamide adenine dinucleotide (NAD+), expression of PARP, Bcl-2, Bax, cytochrome C and caspase 3 activity in the myocardium tissue, levels of serum creatine kinase muscle brain (CK-MB) fraction and troponin I.
RESULTS: Histological and molecular analyses showed that myocardial cells apoptosis were associated with mitochondria injury, with an increase in the amount of PARP and a decrease in ATP and NAD+ levels in model group. In addition, the levels of Bax, cytochrome C and caspase 3 activity, serum levels of CK-MB and troponin I increased, but levels of Bcl-2 significantly decreased. Inhibition of PARP upregulated the levels of ATP, NAD + and Bcl-2, and significantly reduced the activation of PARP and caspase 3, decreased the levels of MDA, cytochrome C, CK-MB and troponin I. As a result, apoptosis in the heart was attenuated.
CONCLUSION: These results indicate that PARP activation may be involved in apoptosis in the heart induced by sepsis and 3-AB could improve it.

Entities:  

Keywords:  3-AB; Sepsis; heart; rats

Mesh:

Substances:

Year:  2015        PMID: 26617692      PMCID: PMC4637777     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  40 in total

1.  Novel therapies for septic shock over the past 4 decades.

Authors:  Anthony F Suffredini; Robert S Munford
Journal:  JAMA       Date:  2011-07-13       Impact factor: 56.272

2.  Critical role of PI3-kinase/Akt activation in the PARP inhibitor induced heart function recovery during ischemia-reperfusion.

Authors:  Krisztina Kovacs; Ambrus Toth; Peter Deres; Tamas Kalai; Kalman Hideg; Ferenc Gallyas; Balazs Sumegi
Journal:  Biochem Pharmacol       Date:  2005-12-06       Impact factor: 5.858

3.  Characteristics of critically ill patients in ICUs in mainland China.

Authors:  Bin Du; Youzhong An; Yan Kang; Xiangyou Yu; Mingyan Zhao; Xiaochun Ma; Yuhang Ai; Yuan Xu; Yushan Wang; Chuanyun Qian; Dawei Wu; Renhua Sun; Shusheng Li; Zhenjie Hu; Xiangyuan Cao; Fachun Zhou; Li Jiang; Jiandong Lin; Erzhen Chen; Tiehe Qin; Zhenyang He; Lihua Zhou
Journal:  Crit Care Med       Date:  2013-01       Impact factor: 7.598

4.  Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China.

Authors:  Baoli Cheng; Guohao Xie; ShangLong Yao; Xinmin Wu; Qulian Guo; Miaoning Gu; Qiang Fang; Qiuping Xu; Dongxin Wang; Yuhong Jin; ShiYing Yuan; Junlu Wang; Zhaohui Du; Yunbo Sun; XiangMing Fang
Journal:  Crit Care Med       Date:  2007-11       Impact factor: 7.598

5.  Role of mitochondrial damage during cardiac apoptosis in septic rats.

Authors:  Li Li; Bang-Chuan Hu; Chang-Qin Chen; Shi-Jin Gong; Yi-Hua Yu; Hai-Wen Dai; Jing Yan
Journal:  Chin Med J (Engl)       Date:  2013       Impact factor: 2.628

6.  Association between mitochondrial dysfunction and severity and outcome of septic shock.

Authors:  David Brealey; Michael Brand; Iain Hargreaves; Simon Heales; John Land; Ryszard Smolenski; Nathan A Davies; Chris E Cooper; Mervyn Singer
Journal:  Lancet       Date:  2002-07-20       Impact factor: 79.321

7.  Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure.

Authors:  David Brealey; Sekhar Karyampudi; Thomas S Jacques; Marco Novelli; Ray Stidwill; Val Taylor; Ryszard T Smolenski; Mervyn Singer
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2003-11-06       Impact factor: 3.619

8.  Effect of PJ-34 PARP-inhibitor on rat liver microcirculation and antioxidant status.

Authors:  Attila Szijártó; Enkhjargal Batmunkh; Oszkár Hahn; Zoltán Mihály; Adám Kreiss; András Kiss; Gábor Lotz; Zsuzsa Schaff; László Váli; Anna Blázovics; Domokos Geró; Csaba Szabó; Péter Kupcsulik
Journal:  J Surg Res       Date:  2007-07-05       Impact factor: 2.192

Review 9.  Bcl-2-family proteins and the role of mitochondria in apoptosis.

Authors:  Tomomi Kuwana; Donald D Newmeyer
Journal:  Curr Opin Cell Biol       Date:  2003-12       Impact factor: 8.382

10.  Intensive care unit-acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shock.

Authors:  Joerg C Schefold; Jeffrey Bierbrauer; Steffen Weber-Carstens
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-12-17       Impact factor: 12.910

View more
  8 in total

1.  The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.

Authors:  Akbar Ahmad; Gabor Olah; David N Herndon; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-05       Impact factor: 8.739

2.  The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis.

Authors:  Akbar Ahmad; Juliana de Camargo Vieira; Aline Haas de Mello; Thais Martins de Lima; Suely Kubo Ariga; Denise Frediani Barbeiro; Hermes Vieira Barbeiro; Bartosz Szczesny; Gábor Törö; Nadiya Druzhyna; Elisa B Randi; Michela Marcatti; Tracy Toliver-Kinsky; András Kiss; Lucas Liaudet; Reinaldo Salomao; Francisco Garcia Soriano; Csaba Szabo
Journal:  Pharmacol Res       Date:  2019-05-06       Impact factor: 7.658

3.  Temporally Distinct Regulation of Pathways Contributing to Cardiac Proteostasis During the Acute and Recovery Phases of Sepsis.

Authors:  Kristen T Crowell; Samantha Moreno; Jennifer L Steiner; Catherine S Coleman; David I Soybel; Charles H Lang
Journal:  Shock       Date:  2018-12       Impact factor: 3.454

Review 4.  PARP Inhibitors: An Innovative Approach to the Treatment of Inflammation and Metabolic Disorders in Sepsis.

Authors:  Weronika Wasyluk; Agnieszka Zwolak
Journal:  J Inflamm Res       Date:  2021-05-06

Review 5.  Mitochondrial Protection by PARP Inhibition.

Authors:  Ferenc Gallyas; Balazs Sumegi
Journal:  Int J Mol Sci       Date:  2020-04-16       Impact factor: 5.923

6.  Adiponectin is protective against endoplasmic reticulum stress-induced apoptosis of endothelial cells in sepsis.

Authors:  Yun Hou; Xi Feng Wang; Zhi Qiang Lang; Yin Chuan Jin; Jia Rong Fu; Xiao Min Xv; Shi Tian Sun; Xin Xin; Lian Shuang Zhang
Journal:  Braz J Med Biol Res       Date:  2018-11-14       Impact factor: 2.590

7.  Adiponectin alleviates blood hypercoagulability via inhibiting endothelial cell apoptosis induced by oxidative stress in septic rats.

Authors:  Yun Hou; Xi-Feng Wang; Zhi-Qiang Lang; Wei Zhao; Yinchuan Jin; Hong-Qin Zhang; Lian-Shuang Zhang
Journal:  Iran J Basic Med Sci       Date:  2018-10       Impact factor: 2.699

Review 8.  Targeting NAD+: is it a common strategy to delay heart aging?

Authors:  Bing Liang; Xin-Lin Liu; Yang Yuan; Wen-Jing Liu; Bing-Huan Huang; Shan-Bo Yang; Yuan-Zhen Gao; Jing-Sen Meng; Meng-Jiao Li; Ting Ye; Chuan-Zhi Wang; Xiao-Kun Hu; Dong-Ming Xing
Journal:  Cell Death Discov       Date:  2022-04-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.